COVID-19 update included
The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

The Europe Tumor Ablation Market would witness market growth of 10% CAGR during the forecast period (2019-2025).
The factors projected to accelerate the demand for advanced tumor ablation technologies over the forecast period include increased inclination of surgeons and patients towards minimally invasive procedures due to benefits such as speedy recovery, patient satisfaction, and lowered turnaround time. Advanced treatments for tumor ablation are generally performed on an outpatient basis and do not involve hospital admission compared to traditional therapies. This also significantly reduces the overall healthcare cost.
One of the facilitating factors of the revolutionary treatment has been the high success rate of tumor ablation, which also makes it one of the most favored tumor therapies where other therapies might not be effective for multiple reasons. The procedure of tumor ablation has been used to treat different types of cancer such as colorectal cancer, lung cancer, liver cancer, prostate cancer, etc.
The ongoing technological advancements have made tumor ablation treatment a safe and painless one especially due to impressive results during and after the procedure. With increasing awareness in the healthcare industry around the world, cancer ablation is becoming increasingly popular for different types of cancer as one of the most favored cancer therapy methods. Hospitals and healthcare centers are recognizing the immense potential of cancer ablation therapy, thereby supporting their patients with the facility that would further assist in facilitating the therapeutic.
Based on Treatment, the market is segmented into Surgical Ablation, Laparoscopic Ablation and Percutaneous Ablation. Based on Technology, the market is segmented into Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation and Other Technology. Based on Application, the market is segmented into Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer and Other Cancer. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Johnson and Johnson (Ethicon, Inc.), Boston Scientific Corporation, Misonix, Inc., EDAP TMS S.A., Theraclion SA, AngioDynamics, Inc., Mermaid Medical A/S, HealthTronics, Inc. (Altaris Capital Partners, LLC), and SonaCare Medical, LLC.
Scope of the Study
Market Segmentation:
By Treatment

  • Surgical Ablation
  • Laparoscopic Ablation and
  • Percutaneous Ablation


By Technology

  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • Irreversible Electroporation and
  • Other Technology


By Application

  • Liver Cancer
  • Breast Cancer
  • Lung Cancer
  • Kidney Cancer
  • Prostate Cancer and
  • Other Cancer


By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Companies Profiled

  • Medtronic PLC
  • Johnson and Johnson (Ethicon, Inc.)
  • Boston Scientific Corporation
  • Misonix, Inc.
  • EDAP TMS S.A.
  • Theraclion SA
  • AngioDynamics, Inc.
  • Mermaid Medical A/S
  • HealthTronics, Inc. (Altaris Capital Partners, LLC)
  • SonaCare Medical, LLC


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free